Publications by authors named "Platts-Mills T"

: IgE to galactose-alpha-1,3-galactose (alpha-gal) is associated with (lone star tick) bites, accounting for the regional distribution of the alpha-gal syndrome (AGS). Longitudinal studies describing risk factors for incident alpha-gal sensitization are lacking. The objective of this project was to assess the incidence of alpha-gal IgE seroconversion and identify associated demographic, occupational, and geographical risk factors among US military personnel.

View Article and Find Full Text PDF

There are limited longitudinal data from non-industrialized settings on patterns and determinants of gut bacterial microbiota development in early childhood. We analysed epidemiological data and stool samples collected from 60 children followed from early infancy to 5 years of age in a rural tropical district in coastal Ecuador. Data were collected longitudinally on a wide variety of individual, maternal, and household exposures.

View Article and Find Full Text PDF
Article Synopsis
  • Snakebite envenoming (SBE) causes over 500,000 deaths or serious injuries annually, and a phase II clinical trial was conducted to evaluate the safety and efficacy of varespladib methyl, an oral treatment, in patients bitten by venomous snakes.
  • The trial, which was double-blind and placebo-controlled, enrolled patients in emergency departments in the USA and India, assessing changes in severity of snakebite symptoms using the Snakebite Severity Score (SSS) after treatment.
  • Results indicated no significant difference in SSS improvement between the varespladib and placebo groups overall, but early treatment (within 5 hours of the bite) showed potential benefits in illness severity and recovery outcomes.
View Article and Find Full Text PDF

Background: IgE to galactose-alpha-1,3-galactose (alpha-gal) is linked to tick bites and an important cause of anaphylaxis and urticarial reactions to mammalian meat. The alpha-gal syndrome (AGS) is recognized as being common in the southeastern United States. However, prevalence studies are lacking and open questions remain about risk factors and clinical presentation of alpha-gal sensitization.

View Article and Find Full Text PDF

Objectives: Around one million United States emergency department (ED) visits annually are due to acute decompensated heart failure (ADHF) symptoms. Characterizing ED symptom presentation of ADHF patients may improve clinical care, yet sex and age differences in ED chief complaints have not been thoroughly investigated. This paper aims to describe differences in chief complaints and comorbid conditions for ED patients with a ADHF diagnosis, stratified by sex and age.

View Article and Find Full Text PDF

The recent recognition of a syndrome of tick-acquired mammalian meat allergy has transformed the previously held view that mammalian meat is an uncommon allergen. The syndrome, mediated by IgE antibodies against the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), can also involve reactions to visceral organs, dairy, gelatin and other products, including medications sourced from non-primate mammals. Thus, fittingly, this allergic disorder is now called the alpha-gal syndrome (AGS).

View Article and Find Full Text PDF

Background: In individuals without symptomatic food allergy, food-specific IgE is considered clinically irrelevant. However, recent studies have suggested that galactose-α-1,3-galactose (alpha-gal) IgE is associated with cardiovascular (CV) disease.

Objective: We sought to determine whether sensitization to common food allergens is associated with CV mortality.

View Article and Find Full Text PDF

Background: IgE to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) is an important cause of allergic reactions to mammalian meat. The "alpha-gal syndrome" is strongly associated with a preceding history of tick bites and in the United States is most commonly reported in parts of the southeast, but there has been limited investigation into national alpha-gal sensitization patterns and the relevance of other risk factors.

Objective: To systematically investigate alpha-gal IgE prevalence, regional patterns, and risk factors.

View Article and Find Full Text PDF
Article Synopsis
  • The rapid advancement of precision diagnostic tools and omic technologies has led to the identification of new disease endotypes for allergic conditions, improving our understanding of diseases beyond just symptoms.
  • This shift has prompted a reevaluation of current disease classifications, ultimately leading to the development of a modern nomenclature for allergic diseases that acknowledges historical classifications.
  • The paper details a comprehensive framework for hypersensitivity reactions, categorizing them into nine types based on mechanisms and responses, with plans for a follow-up article addressing the practical implications in allergy treatment and management.
View Article and Find Full Text PDF
Article Synopsis
  • * Findings revealed an increase in positive test responses from 21% in 1996 to 30% in 2006, which then plateaued in 2017, with cat sensitivities being the most common throughout the years.
  • * Despite a rise in diagnosed asthma, its connection to allergic sensitization weakened, while allergic rhinitis showed a decrease in prevalence but a stronger association with sensitization, indicating changing patterns in allergic disease management.
View Article and Find Full Text PDF

Allergy is an ever-evolving group of disorders, which includes asthma, atopic dermatitis, rhinitis and food allergies and that currently affects over 1 billion people worldwide. This group of disorders has exploded in incidence since around the start of the 20th century, implying that genetics is not solely responsible for its development but that environmental factors have an important role. Here, Fabio Luciani and Jonathan Coquet, in their role as editors at Immunology & Cell Biology, asked nine prominent researchers in the field of allergy to define the term 'allergy', discuss the role of genetics and the environment, nominate the most important discoveries of the past decade and describe the best strategies to combat allergy at the population level going forward.

View Article and Find Full Text PDF

Background: Recent studies have shown deposition of immunoglobulin G4 (IgG4) and food proteins in the esophageal mucosa of eosinophilic esophagitis (EoE) patients. Our aims were to assess whether co-localization of IgG4 and major cow's milk proteins (CMPs) was associated with EoE disease activity and to investigate the proteins enriched in proximity to IgG4 deposits.

Methods: This study included adult subjects with EoE (n = 13) and non-EoE controls (n = 5).

View Article and Find Full Text PDF

The Affordable Care Act aimed to increase use of preventive services by eliminating cost-sharing to consumers. However, patients may be unaware of this benefit or they may not seek preventive services if they anticipate that the cost of potential diagnostic or treatment services will be too high, both more likely among those in high deductible health plans. We used nationally representative private health insurance claims (100% sample of IBM MarketScan) for the United States from 2006 to 2018, restricting the data to enrollment and claims for non-elderly adults who were enrolled for the full plan year.

View Article and Find Full Text PDF

Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE-mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE-mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well-defined, highly pure molecules for component-resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients.

View Article and Find Full Text PDF

Alpha-gal syndrome (AGS) is an allergy to "red meat" and other mammalian products due to immunoglobulin E (IgE) antibodies against the sugar moiety galactose-alpha-1,3-galactose (alpha-gal), which is acquired following tick bites. Clinically, AGS presents with urticaria, abdominal pain, nausea, and occasionally anaphylaxis, and has wide inter- and intra-personal variability. Because symptom onset is generally delayed by 2 to 6 hours after meat consumption, AGS can be easily confused with other causes of urticaria and anaphylaxis, such as chronic spontaneous urticaria (CSU) and mast cell activation syndrome (MCAS).

View Article and Find Full Text PDF

Description: Alpha-gal syndrome is an emerging allergy first described in the early 2000s. The allergy can cause anaphylaxis, gastrointestinal (GI) symptoms, and skin changes one to several hours after ingestion of mammalian products. A GI phenotype that is increasingly recognized manifests with nonspecific symptoms like abdominal pain, diarrhea, nausea or vomiting without predominant skin, respiratory or circulatory symptoms.

View Article and Find Full Text PDF

Background And Aims: Alpha-gal allergy causes a delayed reaction to mammalian meats and has been reported worldwide. Patients with the allergy may present with isolated gastrointestinal (GI) symptoms, but this phenotype is poorly understood.

Methods: We pooled and analyzed symptoms and demographics of patients from two prospective cohorts of patients with a diagnosis of alpha-gal allergy who reacted after eating mammalian meat under observation.

View Article and Find Full Text PDF
Article Synopsis
  • - Snakebite poses a serious global health crisis with high rates of sickness and death, and varespladib has been identified as a potential oral treatment to combat snakebite envenoming (SBE) through its mechanism of blocking venom enzymes.
  • - The BRAVO study aims to assess the safety and effectiveness of oral varespladib-methyl compared to a placebo, using a randomized, double-blind approach involving patients aged 5 and up with acute SBE.
  • - Regulatory approval has been secured for the study in both India and the US, ensuring ethical standards and good clinical practices are followed throughout the trial process.
View Article and Find Full Text PDF

Background: BNT162b2 (Pfizer/BioNTech, Comirnaty) and mRNA-1273 (Moderna, Spikevax) are messenger RNA (mRNA) vaccines that elicit antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (S-RBD) and have been approved by the US Food and Drug Administration to combat the coronavirus disease 2019 (COVID-19) pandemic. Because vaccine efficacy and antibody levels waned over time after the 2-shot primary series, the US Food and Drug Administration authorized a booster (third) dose for both mRNA vaccines to adults in the fall of 2021.

Objective: To evaluate the magnitude and durability of S-RBD immunoglobulin (Ig)G after the booster mRNA vaccine dose in comparison to the primary series.

View Article and Find Full Text PDF

Objective: To test whether providing relevant clinical trial registry information to peer reviewers evaluating trial manuscripts decreases discrepancies between registered and published trial outcomes.

Design: Stepped wedge, cluster-randomised trial, with clusters comprised of eligible manuscripts submitted to each participating journal between 1 November 2018 and 31 October 2019.

Setting: Thirteen medical journals.

View Article and Find Full Text PDF

Introduction: High levels of serum food-specific IgG4 (sIgG4) have been reported in patients with EoE. The objective of this study was to examine whether serum sIgG4 levels to foods and aeroallergens are higher in EoE patients than allergic controls and to investigate the association between sIgG4 and EoE clinical characteristics.

Methods: This was a case-control study nested in a prospective EoE Cohort.

View Article and Find Full Text PDF